Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876065 | 0.83 | GSK3B (0.50) | GSK3BPTPN1HSD11B1KDM4EALDH1A1 | |
| SCHEMBL8881196 | 0.81 | GSK3B (0.44) | GSK3BPTPN1S1PR3 | |
| SCHEMBL8934245 | 0.79 | HSD11B1 (0.36) | HSD11B1S1PR3SLC22A12KDM4EALDH1A1 | |
| SCHEMBL10493922 | 0.78 | CYP2C9 (0.41) | GSK3BPTPN1SLC22A12 | |
| SCHEMBL1303698 | 0.78 | GSK3B (0.54) | GSK3BPTPN1S1PR3 | |
| SCHEMBL11643593 | 0.77 | ADRB2 (0.38) | HSD11B1S1PR3KDM4EALDH1A1 | |
| SCHEMBL11643153 | 0.77 | ADRB2 (0.39) | S1PR3KDM4EALDH1A1GLAGAA | |
| SCHEMBL28782898 | 0.77 | CA1 (0.44) | GSK3BPTPN1HSD11B1GAA | |
| SCHEMBL11643587 | 0.76 | SMN1; SMN2 (0.33) | HSD11B1S1PR3ALDH1A1 | |
| SCHEMBL11642440 | 0.76 | HSD11B1 (0.36) | HSD11B1KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| US-4845262-A | NITRILE CONTAINING | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| EP-0259750-A2 | Aryl ethanol amines, process for their preparation and their use as growth promotors | BAYER AG (DE) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | GSK3B 1914/4885PTPN1 1995/4885HSD11B1 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.